MedTrace Logo

Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children

NCT03866460 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-11-07

No results posted yet for this study

Summary

The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.

Conditions

Interventions

DIAGNOSTIC_TEST

Distortion product otoacoustic emission measurement (DPOAE)

Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.

Sponsors & Collaborators

Principal Investigators

  • Mary Elizabeth Davis, MSN, RN, AOCNS · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
3 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-06
Primary Completion
2024-11-04
Completion
2024-11-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03866460 on ClinicalTrials.gov